Agios Strengthens Team with Key Appointments and Promotion
News May 14, 2012
In addition to the above appointments, John Evans was promoted to vice president of business development and operations.
“The strength of our science and success of our efforts to date are a direct result of the amazing people at Agios,” said Duncan Higgons, chief operating officer of Agios. “John has made significant contributions to our team and company growth over the last several years. Bob and Marion further expand our R&D leadership, bringing a wealth of experience identifying and successfully developing novel and important drugs. People and culture continue to be cornerstones of Agios’ vision to make medicines that can transform patients' lives.”
Dr. DeVita joins Agios after a highly productive career at Merck Research Laboratories in Rahway, NJ, where he was director of medicinal chemistry. Bob is a co-inventor of more than 42 patents and has led efforts to deliver multiple candidates for human study. He received his Ph.D. at the University of Rochester and was a National Science Foundation postdoctoral fellow at the University of Geneva.
Dr. Dorsch most recently served at Sanofi Oncology, where she headed the cancer biology group and oversaw the drug discovery efforts in Cambridge, Mass. Prior to that, Marion directed research for several oncology programs at the Novartis Institutes for Biomedical Research, and also worked at Millennium Pharmaceuticals. She received her Ph.D. in biology from Free University of Berlin, Germany, and was a postdoctoral student at Columbia University in New York.
Mr. Evans joined Agios in 2009 and is responsible for business development, project and portfolio management, communications, and new product planning. Prior to joining Agios, Mr. Evans served as director of product development at Infinity Pharmaceuticals and worked at McKinsey & Company. He earned an MBA from Wharton and a M.S. in biotechnology from the University of Pennsylvania.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Changing microRNA's Presence in Glioblastoma Cells Could Change the Tumor's SubtypeNews
BWH researchers examined a specific microRNA, miR-128, to help identify glioblastoma subtypes and to determine if altering the microRNA's presence in glioblastoma cells could change the tumor's subtype.READ MORE
Comments | 0 ADD COMMENT
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018
EMBL Course: Techniques for Mammary Gland Research
Mar 05 - Mar 09, 2018